Altamira Therapeutics Ltd. (NASDAQ: CYTO) experienced a significant stock surge this morning, rising by 33.92% to $1.91 as of the latest update. This uptick follows the company’s announcement regarding the successful NASAR clinical trial results for its Bentrio nasal spray, a novel treatment for seasonal allergic rhinitis (SAR).
Publication And Outreach
The prestigious journal Allergy, renowned in the field of allergology, published highlights from the NASAR clinical trial on its widely-followed social media channels. This publication, which initially featured a peer-reviewed article in April titled “AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial,” provided comprehensive insights into the trial’s pivotal findings.
Allergy’s extensive reach, with over 250,000 monthly readers and more than two million article downloads annually, has amplified the visibility of these promising results.
Clinical Trial Details And Results
Conducted during the allergy season in Australia, the NASAR trial enrolled 100 patients, randomly assigned in a 1:1 ratio to receive either Bentrio or a saline nasal spray, the current standard of care in drug-free SAR management. Participants administered the treatment three times daily for two weeks.
The trial successfully met its primary efficacy endpoint, demonstrating a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline, along with achieving secondary efficacy endpoints.
Future Prospects And Market Expansion
Altamira Therapeutics aims to expand the availability of Bentrio to additional countries, addressing the daily challenges faced by allergic rhinitis sufferers. Marketed by Altamira Medica AG, an associate company of Altamira Therapeutics, Bentrio is primarily distributed through various channels.
From 2024, Altamira Medica anticipates a significant increase in sales, driven by the product’s launch in new markets. The company is also in the process of finalizing partnership discussions and distribution agreements for the US, Europe, and other key regions, with expectations for substantial market penetration by the end of 2024.
